PER-147-09已完成未知
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
PFIZER S.A., National Cancer Institute of Canada - Clinical Trials Group (NCIC CTG),0 个研究点目标入组 0 人开始时间: 2010年3月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 100（—）
- 性别
- All
入选标准
- •Histologically confirmed diagnosis of non-small cell lung carcinoma. Patients must have an adequate sample either histopathological or cytological (see Section 13), they must give their consent to deliver all samples for this protocol, and the center / pathologist must have agreed to send the samples.
- •Patients must have evidence of illness, but it is not mandatory that it be measurable disease. In order to be considered evaluable for a full or partial response evaluation, patients must have at least one measurable lesion, as follows: X-ray> 20 mm Helical CT scan or physical examination> 10 mm (lymph nodes must be> 15 mm in the short axis Measurable lesions should be outside a previous radiotherapy field, if they are the only site of the disease, unless the disease progression has been documented.
- •Male or female gender, 18 years of age or older.
- •ECOG functional status of 0,1,2 or 3 (see Appendix ü). Patients with a functional status of 3 are eligible on condition that the researcher guarantees that the patient has a reasonable life expectancy (> 6 weeks).
- •The patient can (that is, fluently enough) and is willing to complete the quality of life questionnaires. The baseline evaluation must have been completed. The inability (illiteracy, loss of vision or other equivalent reason) to complete the questionnaires will not be an impediment to the patient´s eligibility for the study. However, even if they have the capacity, the lack of willingness to complete the questionnaires will mean that the patient cannot be chosen for the study.
- •Patient consent must be obtained, in accordance with the requirements of local Institutional Committees and / or Committees of the University of Human Experimentation. It will be the responsibility of the participating local researchers to obtain the necessary local authorization, as well as to indicate in writing to the NCIC CTTCG Study Coordinator that such authorization was obtained, before the study begins at that center. Due to different criteria requirements, a standard consent form for the study will not be provided, but a sample form is provided in Appendix IX. A copy of the total initial approval of the Board of the Institutional Review Committee and the approved consent form must be sent to the central office. The patient must sign the consent form before randomization or registration. Please note that the consent form for this study must include a statement authorizing NCIC CTG and control agencies to inspect and review patient records and medical records (see Section N.® 16 for more details ).
- •Patients should facilitate access for treatment and follow-up. All randomized patients should be followed up and treated in the participating centers. Researchers should ensure that randomized patients in this study are available to fully document treatment, adverse events and follow-up.
- •In accordance with the NCIC CTG policy, treatment according to the protocol must begin within 2 business days of the patient´s randomization.
排除标准
- •Patients who receive concurrent treatment with other experimental medications or anti-cancer therapy.
- •Patients who had suffered untreated and / or uncontrolled cardiovascular conditions and / or had symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication administration, history of atrioventricular conduction defects of 2 and 3. grade). Patients with significant cardiac history, even when controlled, should have LVEF> 50%
- •Patients with untreated brain or meningeal metastases. (CT scans are not required to rule out this, unless there is a clinical assumption of disease in the CNS). Patients with disease in the treated CNS are eligible, with radiological or clinical evidence of stable brain metastases, without evidence of cavitation or hemorrhage in the brain injury, provided that it is asymptomatic and does not require the administration of corticosteroids (there should be steroid administration suspended at least 1 week before randomization).
- •Patients with active or uncontrolled infections, or with serious illnesses or medical conditions that would not allow the patient to manage as established by the protocol,
- •Medium QTc with Bazetts correction> 470msec in the selection ECG or family history of long QT syndrome.
- •Medications that are highly dependent on CYP2D6 for metabolism are prohibited, since PF-804 is a potent CYP2D6 inhibitor in in vitro assays. These inhibitors or inducers are prohibited 7 days before the first dose until the end of treatment with PF-804. These include: Smetoprolol, propafenone, timolol, amitriptyline, clomipramine, desipramine, imipramine, paroxetine, haloperidol, risperidone, thioridazine, codeine, flecainide, mexiletine, tamoxifen, venlafaxine. Lidocaine may be used with clinical monitoring (including telemetry). Opioids such as morphine, oxycodone, dihydrocodeine, hydrocodone, and tramadol may be used as codeine substitutes. The use of these opioids for the alteration of analgesia should be monitored during treatment with PF-804, since they can be partially metabolized by CYP2D6. If PF-804 is administered with medications that are substrates of P-glycoprotein (P-gp) and that have a limited therapeutic index, monitoring for exaggerated effect and / or toxicities is recommended.
- •Inappropriate pregnancy or contraception. Women should be postmenopausal, surgically sterile, or use two reliable forms of contraception. Women of childbearing age should have a pregnancy test and have a negative result within 7 days prior to randomization. Men must be surgically sterile or use a barrier method of contraception.
研究者
相似试验
尚未招募
不适用
A Randomised Double Blind Placebo Controlled Trial of Site Specific Clonidine Patches In Treatment of Neuropathic Wound Pain Following Caesarean Sectioeuropathic wound pain following caesarean sectionNeuropathic wound pain following caesarean sectionReproductive Health and Childbirth - Other surgeryNeurological - Pain managementACTRN12606000064505Tim Short60
进行中（未招募）
不适用
Role of clobazam prophylaxis in children with fits/seizures following fever.CTRI/2018/05/013898DEPARTMENT OF PAEDIATRICS DrSN MEDICAL COLLEGE176
尚未招募
3 期
A study of the effect of Alpha lipoic acid in addition to the usual treatment drug in schizophrenia patientsCTRI/2023/12/060745Dr Ramya R
招募中
2 期
To study the role of vitamin D in improving the clinical outcome in patients with Traumatic Brain Injury in IndiaCTRI/2019/05/019259PGIMER Dr Ram Manohar Lohia Hospital
进行中（未招募）
不适用
A Randomized Double-Blind Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25 mg Twice Weekly in Subjects with Moderate to Severe Persistent AsthmaModerate to severe asthmaticsEUCTR2004-003778-27-FIWyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development120